Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 14, 2022; 28(30): 4061-4074
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4061
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4061
Figure 3 Overview of primary endpoints of phase 3 studies (ADAPT-1, ADAPT-2, L-PLUS 1, and L-PLUS 2).
aP ≤ 0.0001.
- Citation: Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol 2022; 28(30): 4061-4074
- URL: https://www.wjgnet.com/1007-9327/full/v28/i30/4061.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i30.4061